HC Wainwright & Co. reiterated coverage on Balchem with a new price target
$BCPC
Major Chemicals
Industrials
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2025 | $162.00 | Neutral | Rothschild & Co Redburn |
| 3/8/2022 | $170.00 → $155.00 | Buy | HC Wainwright & Co. |
| 2/22/2022 | $175.00 | Neutral → Buy | Sidoti |
| 1/10/2022 | $160.00 → $170.00 | Buy | HC Wainwright & Co. |
| 11/29/2021 | $175.00 | Buy → Neutral | Sidoti |
| 8/2/2021 | $140.00 → $145.00 | Overweight → Equal-Weight | Stephens & Co. |
| 8/2/2021 | $145.00 → $160.00 | Buy | HC Wainwright & Co. |
Rothschild & Co Redburn initiated coverage of Balchem with a rating of Neutral and set a new price target of $162.00
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously
Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00
MONTVALE, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, July 31, 2026, at 11:00 AM Eastern Time (ET) to review second quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Friday, July 31, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. Institutional investors, analysts and other members of the financial community are invited to join the live call by dial
MONTVALE, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solution
MONTVALE, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the Wells Fargo Industrials Conference on June 10, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest qua
3 - BALCHEM CORP (0000009326) (Issuer)
4 - BALCHEM CORP (0000009326) (Issuer)
4 - BALCHEM CORP (0000009326) (Issuer)
8-K - BALCHEM CORP (0000009326) (Filer)
11-K - BALCHEM CORP (0000009326) (Filer)
10-Q - BALCHEM CORP (0000009326) (Filer)
MONTVALE, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, July 31, 2026, at 11:00 AM Eastern Time (ET) to review second quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Friday, July 31, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. Institutional investors, analysts and other members of the financial community are invited to join the live call by dial
MONTVALE, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2026 fiscal first quarter ended March 31, 2026. For the quarter, the Company reported net sales of $270.7 million, net earnings of $40.3 million, adjusted EBITDA(a) of $74.3 million, and free cash flow(a) of $33.8 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record first quarter net sales, adjusted EBITDA, and net earnings, as well as strong cash flows." First Quarter 2026 Financial Highlights: Net sales were $
MONTVALE, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, April 30, 2026, at 11:00 AM Eastern Time (ET) to review first quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. First quarter results will be published prior to the market opening on Thursday, April 30, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. Institutional investors, analysts and other members of the financial community are invited to join the live call by
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)